CTLA4 and pancreatitis: Moreover, George et al. found that CTLA-4 inhibitors had a significantly higher incidence of pancreatitis than PD-1 inhibitors (3.98% vs. 0.94%, p < 0.05) and that combination therapy with CTLA-4 inhibitors and PD-1 inhibitors resulted in a relatively higher incidence of pancreatitis than monotherapy [20].